LabCom GELMECS, a joint-research laboratory between the RMeS U1229 unit and HTL, will announce its roadmap at the 11th World Biomaterials Congress and join the market of hydrogel-based biomaterials for regenerative medicine.
Dr Glenn Prestwich, Science and Innovation Advisor to HTL, will address the first results from this collaboration during the congress.
The creation of a shared laboratory is part of a common desire between the partners to develop hydrogels for the pharmaceutical industry, tissue engineering, and assisted cell therapy.
The partners decided to develop the shared laboratory after working together for four years on an initial application to implement a method of cross-linking of hyaluronic acid.
These biomaterials using silanised hyaluronic acid have reportedly received interest for the creation of injectable bone replacements and cement foams for bone regeneration. A CIFRE thesis co-directed between RMeS and HTL will explore the use of these new biomaterials for osteoarticular regeneration.
The RMeS research unit, which has been developing silanised hydrogels for the past twenty years with more than a dozen potential applications, sees the joint-venture as an opportunity to obtain production of its molecules under cGMP conditions to anticipate clinical trials in the domain of the skeleton and cardiology.
HTL produces molecules that are of particular interest to RMeS for its research projects in skeletal regenerative medicine.
Through this shared laboratory, the challenge is to develop uses of hyaluronic acid and polymers developed by HTL as innovative hydrogel solutions in order to position itself in the market of medical devices and regenerative medicine.
HTL says the laboratory represents an opportunity to promote uses for its hyaluronic acid and its other biopolymers.
